|
Note 7 — (Loss)/earnings per share
|
|
|
|
|
|
|
|
|
|
|
Year Ended March 31, |
|
|
|
2022 |
|
|
2021 |
|
(Loss)/profit for the year attributable to Virax |
|
|
(1,708,827 |
) |
|
|
(650,984 |
) |
Basic (loss)/earnings per share attributable to Virax – Class A |
|
|
(0.67 |
) |
|
|
(0.41 |
) |
Diluted (loss)/earnings per share attributable to Virax – Class A |
|
|
(0.67 |
) |
|
|
(0.41 |
) |
Basic (loss)/earnings per share attributable to Virax – Class B |
|
|
(0.24 |
) |
|
|
(0.79 |
) |
Diluted (loss)/earnings per share attributable to Virax – Class B |
|
|
(0.24 |
) |
|
|
(0.79 |
) |
Basic (loss)/earnings per share is calculated by dividing the (loss)/profit for the year by the weighted average number of ordinary shares in issue during the financial year.
Diluted (loss)/earnings per share
Diluted (loss)/earnings per share is calculated by adjusting the weighted average number of ordinary shares in issue during the year to assume conversion of all dilutive potential ordinary shares. The Company had no dilutive shares as of March 31, 2022 and 2021.
|
|
|
|
|
|
|
|
|
|
|
As of March 31, |
|
|
|
2022 |
|
|
2021 |
|
Weighted average number of ordinary shares used in basic income per share
(Class A ordinary shares) |
|
|
2,550,773 |
|
|
|
1,581,443 |
|
Weighted average number of ordinary shares used in basic income per share
(Class B ordinary shares) |
|
|
7,012,487 |
|
|
|
823,399 |
|
Weighted average number of ordinary shares used as the denominator in
calculating basic (ss)/earnings per share |
|
|
2,550,773 |
|
|
|
1,581,443 |
|
Weighted average number of ordinary shares and potential ordinary shares used
as the denominator in calculating diluted (loss)/earnings per share(1) |
|
|
2,550,773 |
|
|
|
1,581,443 |
|
____________
(1)For the years ended March 31, 2022 and 2021, potential ordinary shares are anti-dilutive, as their inclusion in the diluted loss per share calculation would reduce the loss per share, and hence have been excluded.
|